{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:34:02Z","timestamp":1793745242112,"version":"4.6.1"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1001\/jamaoncol.2019.1029","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T11:00:57Z","timestamp":1560423657000},"page":"1132","source":"Crossref","is-referenced-by-count":434,"title":["Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Shaveta","family":"Vinayak","sequence":"first","affiliation":[{"name":"Case Comprehensive Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, Ohio"},{"name":"currently affiliated with Fred Hutchinson Cancer Research Center, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Center of Breast Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, The West Clinic, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mita","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"McCann","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette R.","family":"Tan","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Atrium Health, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Wahner-Hendrickson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic Rochester, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Anders","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"Department of Medicine, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerburg M.","family":"Wulf","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dillon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Virginia, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Lynce","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine","family":"Zarwan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Lahey Hospital and Medical Center, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Erban","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2013Hematology\/Oncology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Zhou","sequence":"additional","affiliation":[{"name":"TESARO: A GSK Company, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Buerstatte","sequence":"additional","affiliation":[{"name":"TESARO: A GSK Company, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Graham","sequence":"additional","affiliation":[{"name":"TESARO: A GSK Company, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Arora","sequence":"additional","affiliation":[{"name":"TESARO: A GSK Company, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Dezube","sequence":"additional","affiliation":[{"name":"TESARO: A GSK Company, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda L.","family":"Telli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"coi190028r1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10549-012-2315-y","article-title":"Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.","volume":"136","author":"Malorni","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"coi190028r3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ejca.2012.08.005","article-title":"A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.","volume":"49","author":"Gradishar","year":"2013","journal-title":"Eur J Cancer"},{"issue":"10","key":"coi190028r4","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol"},{"key":"coi190028r5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","article-title":"Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERIDIAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.","volume":"70","author":"Miles","year":"2017","journal-title":"Eur J Cancer"},{"issue":"26","key":"coi190028r6","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"34","key":"coi190028r7","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.","volume":"32","author":"O\u2019Shaughnessy","year":"2014","journal-title":"J Clin Oncol"},{"issue":"22","key":"coi190028r8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"961","key":"coi190028r9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3389\/fimmu.2017.00961","article-title":"Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells.","volume":"8","author":"Gibbons Johnson","year":"2017","journal-title":"Front Immunol"},{"issue":"4","key":"coi190028r10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"coi190028r11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-018-4807-x","article-title":"Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.","volume":"171","author":"Telli","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"coi190028r12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity.","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"coi190028r13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia"},{"issue":"4","key":"coi190028r14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer.","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"coi190028r15","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/annonc\/mdv192","article-title":"PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.","volume":"26","author":"Ali","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"coi190028r16","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi190028r17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"coi190028r18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti\u2013PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study.","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"coi190028r19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study.","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol"},{"issue":"21","key":"coi190028r20","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study.","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"coi190028r21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","article-title":"The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality.","volume":"67","author":"Papadimitriou","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"7418","key":"coi190028r22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours.","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"coi190028r23","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0959-8049(18)30285-5","article-title":"101 (PB-002): subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.","volume":"92","author":"Senkus-Konefka","year":"2018","journal-title":"Eur J Cancer"},{"issue":"6","key":"coi190028r24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"coi190028r25","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2018.36.15_suppl.1070","article-title":"Analysis of germline BRCA1\/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).","volume":"36","author":"Eiermann","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi190028r26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"coi190028r27","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi190028r28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.bbrc.2015.05.083","article-title":"The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-\/-) murine model of ovarian cancer.","volume":"463","author":"Huang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"14","key":"coi190028r29","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression.","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"13","key":"coi190028r30","doi-asserted-by":"crossref","first-page":"abstract 1724","DOI":"10.1158\/1538-7445.AM2018-1724","article-title":"Evaluation of niraparib in combination with anti-PD1\/anti\u2013PD-L1 in preclinical models.","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"key":"coi190028r31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/annonc\/mdx376.009","article-title":"Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO\/Keynote-162).","volume":"28","author":"Konstantinopoulos","year":"2017","journal-title":"Ann Oncol"},{"issue":"31","key":"coi190028r32","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update.","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi190028r33","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"coi190028r34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti\u2013PD-1\/PD-L1 treatment for malignancies: a meta-analysis.","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"issue":"12","key":"coi190028r35","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.v7i12","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer.","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"issue":"25","key":"coi190028r36","doi-asserted-by":"publisher","first-page":"17501","DOI":"10.18632\/oncotarget.v9i25","article-title":"BRCA1\/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.","volume":"9","author":"Wieser","year":"2018","journal-title":"Oncotarget"},{"issue":"suppl 4","key":"coi190028r37","doi-asserted-by":"crossref","first-page":"abstract P4-04-01","DOI":"10.1158\/1538-7445.SABCS15-P4-04-01","article-title":"PDL-1 expression in primary breast cancers with germline mutations in BRCA 1 and 2.","volume":"76","author":"Audeh","year":"2016","journal-title":"Cancer Res"},{"issue":"9","key":"coi190028r38","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-18-1891","article-title":"A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1\/2 mutations (ABRAZO).","volume":"25","author":"Turner","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"22","key":"coi190028r39","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"coi190028r40","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"coi190028r41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12916-015-0425-1","article-title":"PARP inhibitors in the management of breast cancer: current data and future prospects.","volume":"13","author":"Livraghi","year":"2015","journal-title":"BMC Med"},{"key":"coi190028r42","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2147\/DDDT","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"coi190028r2","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer version 1.2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed July 2, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-pdf\/5\/8\/1132\/17773642\/jamaoncology_vinayak_2019_oi_190028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T14:29:50Z","timestamp":1663684190000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2735888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.1029","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}